Meet The Speakers
Patricia Casais, M.D., Ph.D., M.Sc., graduated from the University of Buenos Aires, School of Medicine, Argentina in 1990, obtained her Doctorate (2004) and a Master Degree in Clinical Effectiveness (2019) from the same University. She is a Board-certified hematologist and a researcher currently appointed at the Public Health Research Institute, University of Buenos Aires (research) and at the Centro de Hematologia Pavlovsky (clinical practice). After training in Internal Medicine, Casais became a resident in Hematology in the Institute of Hematological Research, National Academy of Medicine, in Buenos Aires (1995-97) and then a Fellow in Thrombosis and Hemostasis at Thrombosis and Hemostasis Department (1997-98), where she stayed as a physician-researcher for 13 years. Later on she moved to the Institute of Epidemiological Research, National Academy of Medicine.
She attended both Latin American Courses on Epidemiology applied to the study of Thrombosis and Hemostasis, sponsored by ISTH in Brazil (2009 and 2019) and was the coordinator of the same Course held in Buenos Aires (2011). In 2012, she was honored with the ISTH Reach-the-World Fellowship to train in Clinical Epidemiology at the Leiden University Medical Center. She was the president of the Argentine Cooperative Group on Hemostasis and Thrombosis from 2011-2014 and was the country coordinator for the World Thrombosis Day (2015-18). Currently, Casais is Co-Chair of the ISTH SSC Subcommittee on Women's Health Issues in T&H, and a member of the ISTH Guidelines and Guidance committee.
Dan Hart, M.D., Ph.D., is a consultant hematologist at The Royal London Hospital Haemophilia centre in the UK and senior lecturer in immunobiology at Barts and The London School of Medicine and Dentistry.
He is also the national hematology lead for the UK National Institute for Health Research.
His research group continues to examine mechanisms of alloreactivity to FVIII and together with colleagues, they have built a broad portfolio of clinical trial participation including novel hemostatic agents and gene therapy.
Maria Elena Rubio Borja
María Elena Rubio Borja is a hematologist with 35 years of experience. She holds an M.Sc. in epidemiology and has worked in clinical medicine, research, clinical trial design and coordination with international groups. She worked more than 20 years at IMSS (Instituto Mexicano del Seguro Social), Hematology Adults Department at Specialty Hospital from La Raza National Medical Center, and coordinated at the National Medical Direction from IMSS for 5 years at the National Bone Marrow Program.
Following her time at public institutions she moved to positions in the pharmaceutical industry (Novo Nordisk, Becton Dickinson, Pfizer) working on a range of projects including submission to Health authorities dossiers, pre-launch and launch activities, training, brand planning, team leading and formation, interaction with patients for societies with rare diseases such as hemophilia and other bleeding disorders, HIV, as well as with international NGOs for such projects.
She has been part of SOMETH (Sociedad Mexicana de Hemostasis y Trombosis) since its founding, participating as an advisory, scientific committee, meetings development particularly in on bleeding disorders.
Ayesha Zia, M.D., is a pediatric hematologist at the Children's Medical Center's Hemostasis Thrombosis Center, and the University of Texas Southwestern School of Medicine. Previous NHF (National Hemophilia Foundation) clinical fellowship award recipient, her clinical/translational research interests are geared toward pediatric patients with bleeding and clotting disorders. Zia also leads the multidisciplinary “Young Women’s Blood Disorders Clinic” at Children's Medical Center, focused on improving the care of adolescent girls with menorrhagia and bleeding disorders as well as girls with thrombophilia first and only program in North Texas that specializes in the diagnosis and treatment of bleeding and clotting disorders and accompanying reproductive problems in young women.
Zia has a particular interest in the use of global coagulation assays, like thromboelatography and thrombin generation, in the diagnosis and management of congenital bleeding and clotting disorders. Current projects are focused on 1) elucidating the biology of hormonal induced thrombosis and predictors of thrombosis in young girls on oral contraceptives, 2) outcomes of thrombosis in the pediatric population including recurrent thrombosis and post-thrombotic syndrome, 3) Improving diagnostic strategies and quality of life in adolescent females with menorrhagia and bleeding disorders and 4) thromboprophylaxis in pediatric patients undergoing orthopedic surgeries. Dr. Zia is also the institutional co-investigator for several clinical trials investigating new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease, and blood clots.